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Abstract
There is considerable interest in the effects of medical marijuana laws (MML) on marijuana use in 
the USA, particularly among youth. The article by Stolzenberg et al. (2015) “The effect of medical 
cannabis laws on juvenile cannabis use” concludes that “implementation of medical cannabis laws 
increase juvenile cannabis use”. This result is opposite to the findings of other studies that 
analysed the same US National Survey on Drug Use in Households data as well as opposite to 
studies analysing other national data which show no increase or even a decrease in youth 
marijuana use after the passage of MML. We provide a replication of the Stolzenberg et al. results 
and demonstrate how the comparison they are making is actually driven by differences between 
states with and without MML rather than being driven by pre and post-MML changes within 
states. We show that Stolzenberg et al. do not properly control for the fact that states that pass 
MML during 2002–2011 tend to already have higher past-month marijuana use before passing the 
MML in the first place. We further show that when within-state changes are properly considered 
and pre-MML prevalence is properly controlled, there is no evidence of a differential increase in 
past-month marijuana use in youth that can be attributed to state MML.
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Introduction
There is considerable interest in the effects of medical marijuana laws (MML) on marijuana 
use in the USA, particularly among youth. The article by Stolzenberg, D’Alessio, and 
Dariano (2015) “The effect of medical cannabis laws on juvenile cannabis use” reports an 
analysis of data from the U.S. National Survey on Drug Use in Households (NSDUH). The 
article concludes that “implementation of medical cannabis laws increase juvenile cannabis 
use” and that there is “compelling evidence supporting the assertion that medical cannabis 
legislation amplifies recreational juvenile cannabis use because the percent of juveniles 
using cannabis increased substantially following the passage of a medical cannabis law.” 
This conclusion of a substantial increase in marijuana use from pre to post-MML passage in 
youth is contrary to the findings from other publications analysing similar NSDUH data 
(Harper, Strumpf, & Kaufman, 2012; Wall et al., 2011, 2012; Wen, Hockenberry, & 
Cummings, 2015) and is also contrary to additional findings from analyses of other large 
national sources of data on youth, specifically the Monitoring the Future (Hasin et al., 2015), 
the Youth Risk Behavior Surveys (YRBS) (Anderson, Hansen, & Rees, 2015; Pacula, David, 
Paul, & Eric, 2015), and the National Longitudinal Survey of Youth (Pacula et al., 2015). 
These other studies found that the prevalence of marijuana use was higher in MML states 
compared to states without MML regardless of when the MML was passed. However, these 
other studies uniformly found either no difference in the prevalence of adolescent marijuana 
use comparing before to after the passage of MML (Anderson et al., 2015; Harper et al., 
2012; Pacula et al., 2015; Wen et al., 2015), or a decrease in marijuana use comparing before 
to after the passage of MML (Hasin et al., 2015). Careful assessment of the analytical 
strategy chosen by Stolzenberg et al. indicates that the statistically significant increased 
association they report between MML and past-month marijuana use is the result of a biased 
comparison and thus, the conclusions of Stolzenberg et al. are not supported by the data.
In this commentary, we provide a replication of the Stolzenberg et al. results and 
demonstrate how the comparison they are making is actually driven by differences between 
states with and without MML rather than being driven by pre and post-MML changes within 
states. We show that Stolzenberg et al. do not properly control for the fact that states that 
pass MML during 2002–2011 (the years of NSDUH data that are available) tend to already 
have higher past-month marijuana use before passing the MML in the first place. We further 
show that when within-state changes are properly considered and pre-MML prevalence is 
properly controlled, there is no evidence of an increase in past-month marijuana use in youth 
that can be attributed to state MML.
The available NSDUH state-level data
A limitation of using the NSDUH data to examine the effects of MML state policy, i.e., 
whether rates of marijuana use change within states after passage of MML, is that the 
NSDUH state-level data used by Stolzenberg et al. were only available for a relatively short 
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time frame, 2002–2011, although states have been passing MML since 1996. Of the 23 
states that currently (as of 2015) have MML, only eight passed their laws between 2002 and 
2011. This leaves 15 states with either no pre-MML or no post-MML data available between 
2002 and 2011 for analysing within state pre and post-MML comparisons.
Fig. 1 shows the raw state NSDUH data used by Stolzenberg et al. in the analysis (not shown 
in the original article). The data are organized into 3 panels to emphasize the 3 different 
types of states (from left to right): (1) the 34 states that did not pass MML by 2011 (note 7 
of these states passed laws after 2011 up until 2015 but are treated as in Stolzenberg et al. as 
“No Law” states); (2) the 8 states that passed MML between 2002 and 2011, for which 
NSDUH pre-and post-MML data are available; and (3) the 8 states that already had MML 
prior to 2002 (in these states, NSDUH data can only inform about post-MML levels of use 
since no pre-MML data are available). Note that the 5 observations plotted over time for 
each state are collapsed by NSDUH into 2-year intervals (i.e. 2002–2003–2004–2005–2006–
2007–2008–2009–2010–2011). In the second panel, representing the 8 states in which MML 
was passed between 2002 and 2011, the dots represent the specific year in which the MML 
was passed, specifically: Arizona (2010), Delaware (2011), Michigan (2008), Montana 
(2004), New Jersey (2010), New Mexico (2007), Rhode Island (2006), and Vermont (2004). 
In the Stolzenberg et al. article and also in this re-analysis of data, a state was treated as 
having the law in the year the law was passed, and in all subsequent years. Because of the 
two-year collapsing of the data by NSDUH, Rhode Island (2006) and New Mexico (2007) 
are treated as passing their MML at the same time (i.e. 2006–2007) and Delaware (2011) is 
treated as passing the MML at the same time as Arizona (2010) and New Jersey (2010) (i.e. 
2010–2011), leading to less pre and post-MML passage information.
Descriptive statistics replication and re-analysis
The average past month marijuana use among 12–17 year olds of the 34 states without 
MML across the 5 time points (10 years) is 6.93% (SD = 1.3%, min = 3.7%, max = 11.8%) 
(simple unweighted average across states). The average use across the same time period in 
the 8 states with “MML prior to 2002” is 8.80% (SD = 1.3%, min = 6.8%, max = 12.3%). 
Importantly, this higher average use of 8.80% in states with MML prior to 2002 cannot be 
used as evidence of a causal effect of MML on increased use, because the NSDUH dataset 
does not provide information on the rates of use in these MML states before they passed 
such laws. In fact, based upon findings from other studies with data from further in the past 
(back to 1991 in Hasin et al., 2015, back to 1993 in Anderson et al., 2015), these states 
appear to have already had higher prevalence of marijuana use before they passed MML.
For the states that passed MML during the window from 2002 to 2011, we summarize the 
pre-MML periods separately from the post MML periods. Table 1 presents the simple 
descriptive means for the 8 states that changed MML status across the 5 time points (10 
years) from 2002 to 2011. Table 1 shows that using the simple within-state differences (for 
the 8 states with available NSDUH data within this time period), the average rate of 
marijuana use increased in 3 states (AZ, DE, NJ) but decreased in 5 states (MI, MT, NM, RI, 
VT). Comparing the simple average of pre-MML marijuana use prevalence (9.44%) to the 
post-MML prevalence (9.35%), the overall average change pre-MML to post-MML in these 
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eight states is −0.1%, thus, not providing any evidence that could be interpreted as an 
increase.
Appropriate analysis of changes in adolescent marijuana use after passage of MML should 
compare the mean marijuana use prevalence in states before the passage of MML to the 
mean of those same states after the passage of MML. Stolzenberg et al. did not make this 
comparison in the descriptive statistics used for Fig. 1 of their manuscript. Their Fig. 1 does 
not compare marijuana use in the same states pre and post-MML, but instead compares 
different states. Each bar for before and after MML passage in the Stolzenberg et al. paper 
represents a different set of states (Supplemental Table S1 in this commentary replicates the 
results and shows the sample size for each bar). The states that passed MML early during 
2002–2011 (VT, MT, RI) already had higher prevalence of marijuana use even before they 
passed MML. Therefore, creating means of post-MML marijuana use by combining these 
states with the states that passed MML later leads to an artificial appearance that marijuana 
use increased post-MML passage because the means are increased through inclusion of 
states that were higher even before they passed MML. Unfortunately, Stolzenberg et al. did 
not recognize this and use their Fig. 1 to make the following conclusion:
Although it is certainly plausible that the prevalence of cannabis use in a state is a 
causal factor in whether or not a state implements a medical cannabis law, Fig. 1 
also shows that with the exception of the 2002–2003 period juvenile cannabis use 
was consistently higher in states following the passage of a medical cannabis law 
than in states that would eventually pass such a law. This finding suggests that the 
implementation of medical cannabis laws increase juvenile cannabis use rather than 
cannabis use influencing the passing of medical cannabis laws.
Contrary to their conclusion, the evidence in Table 1 is much more consistent with 
Stolzenberg et al.’s other plausible conclusion, i.e. that states with higher use were the ones 
that passed MML in the first place, with no evidence of an increase post-MML passage.
Regression modeling replication and re-analysis
Stolzenberg et al. used the panel regression procedure in the LIMDEP software to estimate 
the effect of medical cannabis laws and the control variables on the prevalence of past month 
marijuana use. For our replication and re-analysis we did not have access to the 11 control 
variables used by Stolzenberg et al., but, given that only five control variables were 
statistically significant and all of those variables had small coefficients, suggesting that they 
had little actual effect on the results, we proceeded with re-analyses without them. 
Moreover, our replication of Stolzenberg et al.’s primary regression result yields an 
estimated coefficient similar to their result that adjusts for control variables. Stolzenberg et 
al. describe using a two-way random effects model (commonly applied in econometrics 
when time series and cross-sectional data are combined, e.g. Greene, 1990). Although not 
explicitly shown, the authors appear to have used the following, where Yit is the prevalence 
of past-month marijuana use in state i (i = 1, …, 50) in the 5 time periods t, (t = 2002–2003–
2004–2005–2006–2007–2008–2009–2010–2011)
Model 1
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MMLit is a dichotomous indicator of whether state i has a MML in time period t or not, and 
bi and τt are random intercepts for state and time respectively. In Stolzenberg et al. there 
were 11 additional continuous covariates in Eq. (1), which included state summaries such as 
availability of cannabis and census variables such as percent of fathers in households.
Fitting Model 1 in SAS Proc Mixed (without covariates, code will provided upon request) to 
the NSDUH data from 2002 to 2011, we obtain coefficients β0 = 7.35% with standard error 
(s.e.) = 0.34%, and β1 = 0.93% s.e. = 0.25%, p-value = 0.0002. The positive and significant 
MML effect for β1 corresponds to the major finding in the Stolzenberg article (Table 2 in 
Stolzenberg et al. “Medical Cannabis State Coefficient = 0.861%, s.e. = 0.298%”). This 
positive statistically significant coefficient of 0.861% (0.93% in our replication without 
covariates) was used by Stolzenberg et al. to conclude there was evidence of an increase in 
marijuana use after the passage of MML.
Unfortunately, for addressing the present research question, Model 1 is estimating only two 
means across all states and years, one corresponding to MMLit = 0 which is β0 = 7.35% and 
one corresponding to MMLit = 1 which is β0 + β1 = 7.35% + 0.93% = 8.28%. The two fitted 
means of Model 1 are superimposed in red in Fig. 1. Model 1 rests on two highly 
questionable assumptions: (1) that pre-MML marijuana use in the MML states that passed 
laws prior to 2002 was equal to marijuana use in the non-MML states during 2002–2011 and 
(2) that in the future when non-MML states eventually pass laws, their marijuana use post-
MML will be equal to the post-MML marijuana use in the states that already passed MML 
prior to 2011. More simply, the assumption is that a difference between non-MML and 
MML states exist, but is only attributable to the enactment of the law in the second group, 
and not to other differences between the states. This can be seen because the 34 No MML 
states are the primary contributors to the before passage (i.e. MMLit = 0) mean estimate and 
the 8 states with MML prior to 2002 are the primary contributors to the after passage (i.e. 
MMLit = 1) mean estimate. The 8 states that changed from MMLit = 0 to MMLit = 1 during 
the period contribute to both the pre-MML and post-MML mean estimates, but their 
contribution is swamped by the other states with no change. Hence the β1 effect, interpreted 
by Stolzenberg et al. as indicating the effect on prevalence in a state due to enacting the 
MML, is greatly confounded by between-state differences. We know that states are not 
interchangeable and that laws were not passed randomly. Indeed evidence from the NSDUH 
indicates that the pre-passage years in states that passed laws in 2002–2011 already had 
higher mean marijuana use in youth than the “No Law” states before passing their laws (see 
Table 1, before MML prevalence 9.44% compared to 6.93% for No Law states). Moreover, 
the seven states that passed laws after 2011 up to 2015 also had higher mean MJ use than the 
“No Law” states before passing laws. Specifically, the 7 states which passed laws after 2011 
had mean prevalence before passing laws of 8.2% (SD = 1.5%, min = 5.6%, max 11.8%) 
across 2002–2011 compared to the average use of the 27 which had still not passed laws by 
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2015 which was only 6.6% (SD = 1.0%, min = 3.7%, max = 9.6%). Simply stated, the “No 
Law” states do not make a good (or even reasonable) comparator for estimating pre and 
post-MML changes. The regression model used by Stolzenberg et al. (Model 1) unjustifiably 
extrapolates by using the “No Law” states to estimate the pre-passage mean prevalence and 
compares it to post-passage mean prevalence for other states which do not have pre-passage 
data available.
A simple addition to Model 1 improves this particular confounding problem. By adding one 
more predictor variable indicating whether a state is one that passed a MML or not up to 
2011, we can effectively separate the No Law states out of the estimation of the pre-MML 
prevalence estimate. Define NoMMLi = 0 for the 34 states that did not have laws prior to 
2011, and NoMMLi = 1 for the 16 states that did have laws (regardless of what year it was 




Fitting this model in SAS Proc Mixed we obtain: β0 = 6.94% s.e. 0.34%, β1 = 0.43%, s.e. 
0.28% p-value = 0.123, and β2 = 1.65%, s.e. 0.39% p-value < 0.001. After controlling for 
NoMMLi, the β1 effect of passing MML is not significant and does not indicate a pre–post 
change in the laws. Instead, the large, highly significant effect of β2 indicates there is a 
significantly higher mean in MML states before they pass the laws than in the No MML 
states. Model 2 yields three means: β0 = 6.94%, indicating the mean in the No Law states, β0 
+ β2 = 6.94% + 1.65% = 8.59% indicating the mean in the states with MML before they pass 
the law, and β0 + β1 + β2 = 9.02% indicating the mean in the states with MML after they pass 
the law. The three fitted means of Model 2 are superimposed in blue in Fig. 1.
Fig. 2 shows the residuals from the two models that clearly indicate the biased results that 
arise from Model 1. In Model 1, the “No law” states mean prevalence is overestimated, 
while the means for the states with MML before 2002 and those that passed between 2002 
and 2011 are underestimated. This occurs primarily because the pre-passage observed values 
in the states that passed between 2002 and 2011 are constrained in Model 1 to equal the “No 
Law” mean (because Model 1 only has one fixed parameter for MML). Yet the observed 
prevalence in the 8 states which changed MML during 2002–2011 is already higher before 
passing the laws than the “No law” states. Model 2, on the other hand, shows little or no bias 
because it separates the estimate for the No law states from the pre–post estimates for the 
MML states provided by the states that have passed MML.
Finally, we demonstrate how a fixed effects model can also be used to properly examine the 
pre and post-MML effect. Stolzenberg et al. 2015 dismiss the possibility of using a fixed 
effect model “…because the dummy coded medical cannabis law variable has reduced 
variability”. The minimal variability in the MMLit variable is a symptom of the limited 
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number of states (only 8 states) for which both pre and post (i.e. within state) information is 
available. But lack of variability does not preclude using fixed effects, and other groups have 
analysed data pertaining to the MML question using fixed effects models (Wen et al., 2015 
and Harper et al., 2012 for the NSDUH, and Anderson et al., 2015 and Pacula et al., 2015 
for the YRBS). The fixed effects model is identical to Eq. (1), but rather than assuming 
random distributions for bi and τt as in Eq. (2), they are estimated as separate fixed 
parameters (49 estimates for bi with one state taken as the reference, and 4 estimates for τt 
with 2002–2003 taken as the reference). A Hausman test (Greene, 1990) rejects Model 1 in 
favour of the fixed effects model (m-value = 17.5, df = 1, p-value < .001). Methodological 
arguments in the literature can be found comparing and contrasting the virtues of using fixed 
effects versus random effects, for a recent review see (Clarke, Crawford, Steele, & Vignoles, 
2015). For the present data, the results from using a fixed effect model yield consistent 
results to those of Model 2. Specifically, the coefficient for MMLit from the fixed effects 
model is β1 = 0.33%, s.e. 0.29%, p-value = 0.254 indicating no significant change in 
marijuana use post-MML, as was concluded from Model 2. It is beyond the scope of this 
commentary to repeat all the pros and cons of random versus fixed effects models, but a 
well-known problem of the random effects approach is that bias can occur when there is 
correlation between the predictor of interest and the random effects. By not properly 
controlling for the large mean difference in No MML states versus MML states, the model 
used by Stolzenberg et al. (Model 1) suffers from this bias-inducing correlation, whereas the 
random effects Model 2 which adds one fixed state covariate NoMML alleviates the 
problem. The fixed effects model avoids such bias by taking each state with a change in 
MML as its own control.
Conclusion
There is enormous interest in evidence-based information about the effects of MML on U.S. 
marijuana use, particularly in youth. The problem is that limited information is available that 
can address whether MML are truly causally related to changes in rates of marijuana use. 
NSDUH data clearly illustrate that states with MML had higher average prevalence of 
marijuana use between 2002 and 2011 than states without MML. However, as is well 
known, an association does not necessarily indicate a causal relationship. To build a case for 
a causal relationship between MML and use would require there to be evidence of a change 
in use after passage compared to before. Longitudinal data can be useful to address this 
(repeated cross-sectional data is longitudinal for states), however, longitudinal datasets 
cannot address this question if they do not go back far enough in time to provide information 
on those early adopting states (the 8 with MML prior to 2000) prior to passing the MML. A 
limitation of NSDUH data for addressing the relationship of MML to marijuana use is that 
state-level data are not available prior to 2002. Stolzenberg et al. mistakenly used 
information from the No Law states to substitute for the lack of information in pre-passage 
period for states that now have laws. This biased comparison contributed to a conclusion of 
increased marijuana use among youth due to MMLs. To the uncritical eye, this conclusion 
seems plausible (and potentially worthy of media coverage and political sound bites), but it 
is simply not substantiated by appropriate analysis of the data. When appropriately analysed, 
there is no evidence of a significant differential increase in youth marijuana use post-MML 
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based on the available NSDUH data. While states with MML feature higher rates of 
adolescent marijuana use, to date, no major U.S. national dataset, including the NSDUH, 
supports that MML are a cause of these higher use levels. An important and challenging 
question for future research is to determine the reason(s) that marijuana use is higher in 
states before they pass MML.
It is our hope that this commentary will not only clarify why the conclusion by Stolzenberg 
et al. is problematic, but also demonstrate that careful modeling consideration is needed 
when using observational data to examine the impact of policy changes. Finally, herein we 
only examined the effect of a binary indicator of MML status, but tremendous variability in 
the implementation of MML exists within and across states (Pacula et al., 2015; Smart, 
2015) which presents further modeling challenges but also important opportunities for 
understanding the potential impact of these laws on use in adolescents.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at http://
dx.doi.org/10.1016/j.drugpo.2016.01.015.
References
Anderson, DM.; Hansen, B.; Rees, DI. Medical marijuana laws and teen marijuana use. American Law 
and Economics; 2015. (Review epub April 24)
Clarke P, Crawford C, Steele F, Vignoles A. Revising fixed- and random-effects models: Some 
considerations for policy-relevant education research. Education Economics. 2015; 23(3):259–277.
Greene, WH. Econometric analysis. 1st. New York: Macmillan Publishing Company; 1990. 
Harper S, Strumpf EC, Kaufman JS. Do medical marijuana laws increase marijuana use? Replication 
study and extension. Annals of Epidemiology. 2012; 22(3):207–212. [PubMed: 22285867] 
Hasin D, Wall M, Keyes K, Cerda M, Galea S, Schulenberg J, et al. Medical marijuana laws and 
adolescent marijuana use in the USA from 1991 to 2014: Results from annual, repeated cross-
sectional surveys. Lancet Psychiatry. 2015; 2(7):601–608. [PubMed: 26303557] 
Pacula R, David P, Paul H, Eric S. Assessing the effects of medical marijuana laws on marijuana use: 
The devil is in the details. Journal of Policy Analysis and Management. 2015; 7–31:2015.
Smart, R. The kids aren’t alright but older adults are just fine: Effects of medical marijuana market 
growth on substance use and abuse. 2015. Working Paper UCLA Dissertationhttps://
sites.google.com/site/rosannasmartucla/jmp
Stolzenberg L, D’Alessio S, Dariano D. The effect of medical cannabis laws on juvenile cannabis use. 
International Journal of Drug Policy. 2015 (Online July). 
Wall MM, Poh E, Cerda M, Keyes KM, Galea S, Hasin DS. Adolescent marijuana use from 2002 to 
2008: Higher in states with medical marijuana laws, cause still unclear. Annals of Epidemiology. 
2011; 21(9):714–716. [PubMed: 21820632] 
Wall MM, Poh E, Cerda M, Keyes KM, Galea S, Hasin DS. Commentary on Harper S, Strumpf EC, 
Kaufman JS. Do medical marijuana laws increase marijuana use? Replication study and extension. 
Annals of Epidemiology. 2012; 22(7):536–537. [PubMed: 22534177] 
Wen H, Hockenberry JM, Cummings JR. The effect of medical marijuana laws on adolescent and adult 
use of marijuana, alcohol, and other substances. Journal of Health Economics. 2015; 42:64–80. 
[PubMed: 25863001] 
Wall et al. Page 8






















State level NSDUH prevalence of past month marijuana (MJ) use for 12–17 year olds in all 
50 states from 2002 to 2011 stratified by MML status with overlay of fitted means from 
regression Model 1 (red) and Model 2 (blue). *Dots in middle panel indicate year MML 
passed for those 8 specific states (abbreviation of states shown) that passed during 2002–
2011. The two fitted regression lines for each Model in the middle panel indicate pre and 
post-MML passage fitted mean values. Pre is the line staggered to the left, post is the line 
staggered to the right. Note: State-level NSDUH data used herein for 2002–2003, 2004–
2005, 2006–2007, 2008–2009 were compiled at an earlier date from SAMHSA http://
www.samhsa.gov/samhda. As of 11/9/2015 the web archive is unavailable. Data for 2010–
2011 are available from http://archive.samhsa.gov/data/NSDUH/2k11State/NSDUHsae2011/
ChangeTabs/NSDUHsaeChangeTabs2011.htm. (For interpretation of the references to 
colour in this legend, the reader is referred to the web version of the article.)
Wall et al. Page 9






















Residuals from Models 1 and 2. *MJ is marijuana.
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